Page 122 - 《中国药房》2022年6期

metastatic non-small cell lung cancer treated with ni- [41] KIM H I，KIM M，LEE S H，et al. Development of thyroid
volumab：a pooled exploratory analysis from a global dysfunction is associated with clinical response to PD-1
cohort[J]. Cancer Immunol Immunother，2020，69（7）： blockade treatment in patients with advanced non-small
1177-1187. cell lung cancer[J]. Oncoimmunology，2017，7（1）：
[31] NOGUCHI S，SUMINAGA K，KAKI T，et al. Correlation e1375642.
of immune-related adverse events and effects of pembroli- [42] LISBERG A，TUCKER D A，GOLDMAN J W，et al.
zumab monotherapy in patients with non-small cell lung Treatment-related adverse events predict improved clini-
cancer[J]. Lung Cancer（Auckl），2020，11：53-57. cal outcome in NSCLC patients on KEYNOTE-001 at a
[32] RIUDAVETS M，MOSQUERA J，GARCIA-CAMPELO R， single center[J]. Cancer Immunol Res，2018，6（3）：288-
et al. Immune-related adverse events and corticosteroid 294.
use for cancer-related symptoms are associated with efficacy [43] TOI Y，SUGAWARA S，KAWASHIMA Y，et al. Associa-
in patients with non-small cell lung cancer receiving tion of immune-related adverse events with clinical bene-
anti-PD-（L）1 blockade agents[J]. Front Oncol，2020，10： fit in patients with advanced non-small-cell lung cancer
1677. treated with nivolumab[J]. Oncologist，2018，23（11）：
[33] AHN B C，PYO K H，XIN C F，et al. Comprehensive ana- 1358-1365.
lysis of the characteristics and treatment outcomes of [44] OSORIO J C，NI A，CHAFT J E，et al. Antibody-mediated
patients with non-small cell lung cancer treated with thyroid dysfunction during T-cell checkpoint blockade in
anti-PD-1 therapy in real-world practice[J]. J Cancer Res patients with non-small-cell lung cancer[J]. Ann Oncol，
2017，28（3）：583-589.
Clin Oncol，2019，145（6）：1613-1623.
[45] MEYERS D E，BANERJI S. Biomarkers of immune
[34] BERNER F，BOMZE D，DIEM S，et al. Association of
checkpoint inhibitor efficacy in cancer[J]. Curr Oncol，
checkpoint inhibitor-induced toxic effects with shared can-
2020，27（Suppl 2）：S106-S114.
cer and tissue antigens in non-small cell lung cancer[J].
[46] PRELAJ A，TAY R，FERRARA R，et al. Predictive bio-
JAMA Oncol，2019，5（7）：1043-1047.
markers of response for immune checkpoint inhibitors in
[35] CORTELLINI A，CHIARI R，RICCIUTI B，et al. Correla-
non-small-cell lung cancer[J]. Eur J Cancer，2019，106：
tions between the immune-related adverse events spec-
144-159.
trum and efficacy of anti-PD1 immunotherapy in NSCLC
[47] 石元朝，关泉林.非小细胞肺癌免疫治疗疗效预测的研究
patients[J]. Clin Lung Cancer，2019，20（4）：237-247.e1.
进展[J].现代肿瘤医学，2022，30（2）：360-364.
[36] GRANGEON M，TOMASINI P，CHALEAT S，et al. Asso-
[48] AKAMATSU H，MURAKAMI E，OYANAGI J，et al. Im-
ciation between immune-related adverse events and effica-
mune-related adverse events by immune checkpoint inhi-
cy of immune checkpoint inhibitors in non-small-cell lung
bitors significantly predict durable efficacy even in
cancer[J]. Clin Lung Cancer，2019，20（3）：201-207.
responders with advanced non-small cell lung cancer[J].
[37] KSIENSKI D，WAI E S，CROTEAU N，et al. Efficacy of
Oncologist，2020，25（4）：e679-e683.
nivolumab and pembrolizumab in patients with advanced
[49] 王汉萍，郭潇潇，周佳鑫，等.免疫检查点抑制剂相关肺炎
non-small-cell lung cancer needing treatment interruption
的 临 床 诊 治 建 议 [J]. 中 国 肺 癌 杂 志 ，2019，22（10）：
because of adverse events：a retrospective multicenter 621-626.
analysis[J]. Clin Lung Cancer，2019，20（1）：e97-e106. [50] WANG D Y，SALEM J E，COHEN J V，et al. Fatal toxic
[38] RICCIUTI B，GENOVA C，DE GIGLIO A，et al. Impact effects associated with immune checkpoint inhibitors：a
of immune-related adverse events on survival in patients systematic review and meta-analysis[J]. JAMA Oncol，
with advanced non-small cell lung cancer treated with nivo- 2018，4（12）：1721-1728.
lumab：long-term outcomes from a multi-institutional [51] WANG W，GU X，WANG L，et al. The prognostic impact
analysis[J]. J Cancer Res Clin Oncol，2019，145（2）：479- of mild and severe immune-related adverse events in non-
485. small cell lung cancer treated with immune checkpoint in-
[39] TOI Y，SUGAWARA S，SUGISAKA J，et al. Profiling pre- hibitors：a multicenter retrospective study[J]. Cancer Im-
existing antibodies in patients treated with anti-PD-1 the- munol Immunother，2021：2021Nov24.
rapy for advanced non-small cell lung cancer[J]. JAMA [52] FREEMAN-KELLER M，KIM Y，CRONIN H，et al. Ni-
Oncol，2019，5（3）：376-383. volumab in resected and unresectable metastatic melano-
[40] HARATANI K，HAYASHI H，CHIBA Y，et al. Associa- ma：characteristics of immune-related adverse events and
tion of immune-related adverse events with nivolumab ef- association with outcomes[J]. Clin Cancer Res，2016，22
ficacy in non-small-cell lung cancer[J]. JAMA Oncol， （4）：886-894.
2018，4（3）：374-378. （下转第768页）

·752 · China Pharmacy 2022 Vol. 33 No. 6 中国药房 2022年第33卷第6期